Ruud P Dings, PhD

Research Program: Cancer Therapeutics Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Radiation Oncology

Cancer Research Interest

• Disease Site Focus: Cutaneous/Melanoma, GI, Gynecology, Head and Neck, Thoracic/ Lung
• Research Focus Area: Treatment, Carcinogenesis
• Type of Research: Basic
• Research Interest Statement: Primary areas of investigation are aimed at enhancing our understanding of cancer biology to discover and develop improved methods for cancer treatment. Particularly our laboratory major research interest is the tumor microenvironment, with emphasis on the interplay between the immune system and the tumor stroma. This is includes but is not limited to: - Drug discovery, design and development (e.g. cancer, stroma, resistance) - Tumor microenvironment (e.g. vessel normalization, physiology, immunology) - Dysbiosis and carcinogenesis (e.g. microbiome of the GI tract, lung and skin) - Cancer glycobiology (e.g. galectins) - Conventional treatments (e.g. combinations, optimizations, new mechanisms)

Contact Information

• Email Address: RPMDINGS@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• US Department of Defense – W81XWH-21-1-0577
  “Antibiotic-Induced Dysbiosis Promotes Lung Metastasis”
  Principal Investigator
  09/30/21 – 09/29/24
• NIH/Nat. Cancer Institute – 1R01CA245083
  “Improvement of cellular immunotherapy during dysbiosis”
  Principal Investigator
  09/15/21 – 08/31/26
• NIH/Nat. Cancer Institute – 1R01CA238025
  “Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopy- Resubmission”
  Principal Investigator
  08/13/19 – 07/31/25

Publications

• Jenkins SV, Shah S, Jamshidi-Parsian A, [et al., including Dings RPM]. Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance. Radiation research. 2024 201(2):174-187. PMID: 38329819. PMCID: PMC10993299.
• Jenkins SV, Jung S, Jamshidi-Parsian A, [et al., including Dings RPM]. Morphological Effects and In Vitro Biological Mechanisms of Radiation-Induced Cell Killing by Gold Nanomaterials. ACS applied materials & interfaces. 2023. PMID: 38059477.
• Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, [et al., including Dings RPM]. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis. 2022. PMID: 36459240. PMCID: PMC10119234.
• Dings RPM, Kumar N, Mikkelson S, [et al.]. Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activity. Biochemistry and biophysics reports. 2021 28:101116. PMID: 34485713. PMCID: PMC8408429.
• Jenkins SV, Alimohammadi M, Terry AS, [et al., including Dings RPM]. Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. Angiogenesis. 2021. PMID: 33629198. PMCID: PMC8295215.
• Safina I, Alghazali KM, Childress L, [et al., including Dings RPM]. Dendritic cell biocompatibility of ether-based urethane films. Journal of applied toxicology : JAT. 2021. PMID: 33417269. PMCID: PMC8263788.
• Safina I, Al Sudani ZAN, Hashoosh A, [et al., including Dings RPM]. Gold nanorods enhance different immune cells and allow for efficient targeting of CD4+ Foxp3+ Tregulatory cells. PloS one. 2021 16(8):e0241882. PMID: 34460818. PMCID: PMC8404976.
• Johnsrud AJ, Jenkins SV, Jamshidi-Parsian A, [et al., including Dings RPM]. Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiation research. 2020 194(6):688-697. PMID: 33348372. PMCID: PMC8008989.
• Dadgar S, Troncoso JR, Siegel ER, [et al., including Dings RPM]. Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. Neoplasia (New York, N.Y.). 2020 23(1):49-57. PMID: 33220616. PMCID: PMC7683290.
• Jenkins SV, Robeson MS 2nd, Griffin RJ, [et al., including Dings RPM]. Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer research. 2019 79(23):5999-6009. PMID: 31591154. PMCID: PMC6891208.